SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

4 marketing jobs

Amylyx Pharmaceuticals logo
4 hrs ago

Director, Access Marketing

Amylyx Pharmaceuticals

Cambridge, MA (Remote)Full time$224K/yr – $252K/yr
Amylyx Pharmaceuticals logo
7 days ago

Associate Director, Media Strategy & Execution

Amylyx Pharmaceuticals

Cambridge, MA (Hybrid)Full time$173K/yr – $203K/yr
Amylyx Pharmaceuticals logo
10 days ago

Senior Manager, Corporate Communications

Amylyx Pharmaceuticals

Cambridge, MA (Remote)Full time$148K/yr – $166K/yr
Amylyx Pharmaceuticals logo
5 months ago

Associate Director, HCP Marketing

Amylyx Pharmaceuticals

Cambridge, MA (Remote)Full time$193K/yr – $217K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

4 jobs
Amylyx Pharmaceuticals logo

Director, Access Marketing

Amylyx Pharmaceuticals

Cambridge, MA (Remote)

$224K/yr - $252K/yrIn-houseFull-timeDirector/executive8+ years exp.
4 hrs ago
Amylyx Pharmaceuticals logo

Associate Director, Media Strategy & Execution

Amylyx Pharmaceuticals

Cambridge, MA (Hybrid)

$173K/yr - $203K/yrIn-houseFull-timeDirector/executive8+ years exp.
7 days ago
Amylyx Pharmaceuticals logo

Senior Manager, Corporate Communications

Amylyx Pharmaceuticals

Cambridge, MA (Remote)

$148K/yr - $166K/yrIn-houseFull-timeSenior level6+ years exp.
10 days ago
Amylyx Pharmaceuticals logo

Associate Director, HCP Marketing

Amylyx Pharmaceuticals

Cambridge, MA (Remote)

$193K/yr - $217K/yrIn-houseFull-timeSenior level8+ years exp.
5 months ago
Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals

Director, Access Marketing

Cambridge, MA (Remote)

$224K/yr – $252K/yrDirector/Executive8+ years expFull time

Posted 4 hrs ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own the development and execution of market access strategy and resources for avexitide, guiding cross-functional teams to create compliant, impactful payer, HCP office, and patient services materials.

  • Lead payer and access marketing materials in collaboration with HEOR, Medical Affairs, and National Accounts
  • Develop resources for HCP offices and patient services programs and monitor coverage across PBMs, payers, and government plans

Job Description

Responsibilities

  • Own the development of access marketing strategy, messaging, value narratives, and customer-facing resources for avexitide, supporting market access field teams, patient services, and the field sales team.
  • Lead the development of avexitide payer and access marketing resources, including Pre-Approval Information Exchange (PIE) presentations, payer value proposition (PVP) materials, disease education resources, and budget impact models, in close collaboration with HEOR, Medical Affairs, and the National Accounts team.
  • Lead the development of access materials, including HCP office staff educational resources and patient services program marketing assets, in strong partnership with Patient Services, Trade, HCP Marketing, and other cross-functional stakeholders
  • Use internal and external resources to track, monitor, and improve avexitide coverage across commercial access customers (PBMs and payers) and government customer types (Medicare, Medicaid, VA, DoD, and TRICARE).
  • Create PBM, payer, health system, specialty pharmacy, trade, and provider office materials that communicate product value, coverage considerations, reimbursement pathways, affordability support, and patient services offerings.
  • Partner with Market Access, Brand Marketing, Patient Services, Medical Affairs, HEOR/RWE, Legal, Regulatory, Compliance, Field Access, Training, and Commercial Operations to ensure materials are accurate, compliant, differentiated, and actionable.
  • Use customer insights, payer dynamics, coverage trends, and field feedback to refine access messaging and identify unmet educational needs.
  • Manage agency partners and vendors through briefing, content development, review, production, deployment, and measurement.
  • Establish success metrics for access marketing initiatives and evaluate effectiveness through field feedback, customer engagement, and business impact indicators.
  • Champion materials through medical, regulatory, and legal review.

Requirements

  • Bachelor’s degree required; advanced degree such as MBA, MPH, PharmD, or related discipline preferred.
  • 8+ years of experience in pharmaceutical/biotech market access marketing, payer marketing, patient services marketing, managed markets, or related commercial roles.
  • Experience building payer resources, such as PIE presentations, PVP materials, and disease state education
  • Experience building HCP office support and patient services resources, such as prior authorization and appeals kits, medical exception resources, coding, billing, and reimbursement guides.
  • Strong experience using access platforms to monitor coverage and policy and building action plans to support launch/post-launch environments.
  • Experience with rare diseases, specialty products, launches, or patient support programs preferred.
  • Proven ability to develop compliant, customer-facing market access resources from strategy through execution.
  • Experience leading agency partners, materials review processes, cross-functional teams, and launch or lifecycle access initiatives.
  • Ability and willingness to travel occasionally
Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

3.9 Glassdoor

We have an audacious mission to develop novel therapies for communities with high unmet needs. Where others see challenges, Amylyx sees opportunities that we pursue with urgency, rigorous science, and unwavering commitment. We explore scientific approaches that are tailored to diseases where we can make the greatest difference, agnostic of modality, in order to usher in a new era of advancements.See our community guidelines here: https://www.amylyx.com/social-media-guidelinesPlease be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.

Founded in 2014
Cambridge, Massachusetts, USA
158 employees (12 in marketing)
www.amylyx.com
74% recommend to a friend

Salaries

Posted range

$224K/yr – $252K/yr

Taken straight from the job posting.

See all Amylyx Pharmaceuticals salaries

Marketing Team

Marketing Team Size
10 (6% of company)
Median Career Experience
20 years
Median Tenure
3.3 years
Marketing Roles Posted (Last 30 Days)
3

People

Founders / CEO

Joshua Cohen
Joshua Cohen
Co-Founder and Co-CEO at Amylyx Pharmaceuticals
At the company for 13 years 7 months
Justin Klee
Justin Klee
Co-Founder & Co-CEO
At the company for 13 years 7 months

HR / Recruitment

Martin Mitchell
Martin Mitchell
Senior Vice President, Human Resources and Talent Acquisition
At the company for 3 years 3 months
Amy Carroll
Amy Carroll
Lead, Talent Acquisition Partner
At the company for 5 years 9 months

Marketing Leadership

Martin Mitchell
Martin Mitchell
Senior Vice President, Human Resources and Talent Acquisition
At the company for 3 years 3 months
Nayiri Baljian
Nayiri Baljian
Vice President, Marketing and Product Strategy
At the company for 2 years 9 months
Kendall Moore
Kendall Moore
Associate Director, Community (Patient) Marketing
At the company for 1 year 3 months
Katrina Carey
Katrina Carey
Director, Marketing – Avexitide Brand Lead
At the company for 4 years 10 months

Funding

Total Funding
$623.5M
Last Raise
$175M
Post IPO Equity, 6 months ago

Funding History

  • Sep 2025
    Post IPO Equity • $175M
  • Oct 2022
    Post IPO Equity • $246.3M
  • Jul 2021
    Series C • $135M

Traffic Signals

Monthly Visitors
13.3K
Traffic Source Mix
Search
43.7%
Direct
42.3%
Referral
5.8%
Social
6.8%
Paid
1.3%

Headcount Trend

Current headcount: ~158

Recent News

What the charts say about Amylyx Pharmaceuticals Inc. today - 2025 Year in Review & Stepwise Trade Signal Guides
Nov 20, 2025 • newser.com
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead
Nov 17, 2025 • The Motley Fool
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead
Nov 17, 2025 • Nasdaq
Amylyx Pharmaceuticals (AMLX): Valuation Insights Following Improved Q3 2025 Financial Performance
Nov 16, 2025 • simplywall.st
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
Nov 13, 2025 • Business Wire
Is Amylyx (AMLX) Reshaping Its Investment Case With Improved Losses and Avexitide’s Path to Market?
Nov 13, 2025 • simplywall.st
Amylyx Pharmaceuticals Ends PSP Trial of AMX0035 - AFTD
Nov 10, 2025 • AFTD - The Association for Frontotemporal Degeneration
Amylyx Pharmaceuticals (AMLX): Assessing Valuation After a Sharp Rally and Recent Pullback
Nov 10, 2025 • Yahoo Finance
December 2026 Options Now Available For Amylyx Pharmaceuticals (AMLX)
Nov 7, 2025 • Nasdaq
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2025 Earnings Call Transcript
Nov 7, 2025 • Insider Monkey
Notice to Long-Term Shareholders of Amylyx Pharmaceuticals,
Nov 6, 2025 • GlobeNewswire
Amylyx Pharmaceuticals Shares Lower After Q3 Results
Nov 6, 2025 • MarketScreener
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
Nov 6, 2025 • Business Wire
Amylyx Pharma Q3 loss narrows
Nov 6, 2025 • TradingView
Amylyx Pharmaceuticals: Positive Earnings Call Highlights Progress and Challenges
Nov 6, 2025 • TipRanks
Should Amylyx Pharmaceuticals' Sharply Reduced Net Losses Prompt a Rethink by AMLX Investors?
Nov 6, 2025 • Sahm
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 3, 2025 • Business Wire
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Oct 30, 2025 • Business Wire
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Oct 30, 2025 • Bakersfield.com
Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Oct 27, 2025 • Business Wire
Amylyx Pharmaceuticals Advances ALS Treatment with Promising Study Update
Oct 27, 2025 • TipRanks
BofA Securities Lifts Amylyx Pharmaceuticals Inc. (AMLX) Price Target Amid Bolstered Balance Sheet
Oct 26, 2025 • Insider Monkey
Amylyx Pharmaceuticals (AMLX): Assessing Valuation After a Dramatic 260% Share Price Surge
Oct 26, 2025 • Yahoo Finance
Is Amylyx Pharmaceuticals Inc. stock a defensive play in 2025 - 2025 Market WrapUp & High Accuracy Swing Entry Alerts
Oct 25, 2025 • newser.com
Is Amylyx Pharmaceuticals Inc. stock attractive for long term wealth building - Weekly Market Summary & Low Drawdown Investment Ideas
Oct 25, 2025 • newser.com
Trend analysis for Amylyx Pharmaceuticals Inc. this week - July 2025 Action & Daily Profit Focused Stock Screening
Oct 25, 2025 • newser.com
Will Amylyx Pharmaceuticals Inc. stock deliver better than expected guidance - July 2025 Short Interest & Weekly Breakout Opportunity Watchlist
Oct 25, 2025 • newser.com
Is Amylyx Pharmaceuticals Inc. stock a defensive play in 2025 - Portfolio Value Summary & AI Enhanced Market Trend Forecasts
Oct 25, 2025 • newser.com
Trend analysis for Amylyx Pharmaceuticals Inc. this week - 2025 Volatility Report & AI Powered Trade Plan Recommendations
Oct 25, 2025 • newser.com
Will Amylyx Pharmaceuticals Inc. price bounce be sustainable - Fed Meeting & Real-Time Volume Analysis Alerts
Oct 25, 2025 • newser.com
Measuring Amylyx Pharmaceuticals Inc.’s beta against major indices - July 2025 Trade Ideas & Fast Moving Stock Trade Plans
Oct 25, 2025 • newser.com
Assessing Amylyx Pharmaceuticals (AMLX) Valuation Following a 74% Three-Month Share Price Surge
Oct 25, 2025 • simplywall.st
Is Amylyx Pharmaceuticals Inc. stock a defensive play in 2025 - Weekly Loss Report & Weekly Sector Rotation Insights
Oct 24, 2025 • newser.com
Is Amylyx Pharmaceuticals Inc. stock attractive for long term wealth building - Weekly Earnings Recap & Real-Time Volume Trigger Notifications
Oct 24, 2025 • newser.com
Trend analysis for Amylyx Pharmaceuticals Inc. this week - Market Trend Review & Technical Buy Zone Confirmations
Oct 24, 2025 • newser.com
Has Amylyx Pharmaceuticals (AMLX) Outpaced Other Medical Stocks This Year?
Oct 24, 2025 • Yahoo Finance
Has Amylyx Pharmaceuticals (AMLX) Outpaced Other Medical Stocks This Year?
Oct 24, 2025 • Nasdaq
What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now?
Oct 24, 2025 • Yahoo Finance
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
Oct 23, 2025 • Eastern Progress
What’s the recovery path for long term holders of Amylyx Pharmaceuticals Inc. - July 2025 Setups & Expert Curated Trade Setups
Oct 23, 2025 • newser.com
Using economic indicators to assess Amylyx Pharmaceuticals Inc. potential - 2025 Volume Leaders & Daily Price Action Insights
Oct 21, 2025 • newser.com
Tools to monitor Amylyx Pharmaceuticals Inc. recovery probability - Market Rally & Smart Money Movement Tracker
Oct 21, 2025 • newser.com
Will Amylyx Pharmaceuticals Inc. price bounce be sustainable - Trade Analysis Report & Growth Oriented Trade Recommendations
Oct 21, 2025 • newser.com
Important Notice to Long-Term Shareholders of Amylyx
Oct 20, 2025 • GlobeNewswire
How the Class Action Investigation Into Relyvrio Disclosures at Amylyx Pharmaceuticals (AMLX) Has Changed Its Investment Story
Oct 19, 2025 • Sahm
Amylyx Pharmaceuticals (AMLX): Assessing Valuation After Class Action Probe Challenges Relyvrio Demand Claims
Oct 17, 2025 • simplywall.st
Important Notice to Long-Term Shareholders of Amylyx
Oct 17, 2025 • GlobeNewswire
Is AMLX Stock a Solid Choice Right Now?
Oct 16, 2025 • The Globe and Mail
AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges
Oct 16, 2025 • GlobeNewswire
Attention Long-Term Shareholders of Amylyx Pharmaceuticals,
Oct 8, 2025 • GlobeNewswire
Amylyx Pharmaceuticals (AMLX): A Fresh Look at Valuation Following New Legal Investigation
Oct 8, 2025 • simplywall.st
Amylyx Faced With Big Rally Reality Check: Why I Choose To Hold (NASDAQ:AMLX)
Oct 8, 2025 • Seeking Alpha
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
Oct 6, 2025 • PR Newswire
Have Amylyx Pharmaceuticals Insiders Been Selling Stock?
Oct 5, 2025 • simplywall.st
Amylyx stock price target raised to $16 from $14 at BofA Securities
Oct 3, 2025 • Investing.com
Amylyx Will Battle Investor Suit Over Revoked ALS Treatment (1)
Oct 3, 2025 • Bloomberg Law News
Amylyx Pharmaceuticals Executives Cash In on Major Stock Sales!
Oct 2, 2025 • TipRanks
Amylyx Pharmaceuticals Reaches Analyst Target Price
Sep 30, 2025 • Nasdaq
Hope for Rare Pediatric Disease Voucher Reignited as House Bill Passes Committee
Sep 19, 2025 • BioSpace
WilmerHale Advises Underwriters in Public Offering of Amylyx Pharmaceuticals
Sep 18, 2025 • WilmerHale
Guggenheim raises Amylyx Pharmaceuticals stock price target on PBH potential
Sep 15, 2025 • Investing.com
Potential FDA Approval on the Way for Amylyx’s AMX0035 in ALS Ahead of Time
Sep 15, 2025 • Clinical Trials Arena
Will Amylyx Pharmaceuticals’ (AMLX) $175 Million Capital Raise Reshape Its Pipeline Ambitions?
Sep 13, 2025 • Yahoo Finance
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
Sep 10, 2025 • Business Wire
Amylyx Pharmaceuticals at H.C. Wainwright: Strategic Advances in Rare Diseases
Sep 10, 2025 • Investing.com
Amylyx Pharmaceuticals Announces $164 Million Stock Offering
Sep 10, 2025 • TipRanks
Amylyx 17.5M share Spot Secondary priced at $10.00
Sep 10, 2025 • thefly.com
Amylyx Pharmaceuticals Prices $175 Million Common Stock Offering
Sep 10, 2025 • MarketScreener
Amylyx Pharmaceuticals announces pricing of $175 million underwritten public offering of common stock
Sep 10, 2025 • MarketScreener
Waldencast, Danaher, Asset Entities
Sep 10, 2025 • Reuters
Potbelly, Joby, Talen Energy
Sep 10, 2025 • Reuters
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
Sep 10, 2025 • MarketScreener
Amylyx announces proposed public offering of common stock
Sep 9, 2025 • MSN
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
Sep 9, 2025 • Business Wire
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
Sep 9, 2025 • Morningstar.com
Transcript : Amylyx Pharmaceuticals, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-08-2025 04
Sep 8, 2025 • MarketScreener
New Wave of ALS Therapies Signals Renaissance After Incremental Regression
Sep 2, 2025 • BioSpace
Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation
Sep 1, 2025 • simplywall.st
Amylyx Discontinues AMX0035 Program in Supranuclear Palsy Following Disappointing Phase 2b Data
Aug 28, 2025 • NeurologyLive
Amylyx Pharmaceuticals falls after US FDA withdraws approval for ALS drug
Aug 28, 2025 • TradingView
Amylyx Pharmaceuticals Discontinues Orion Program of Ax0035
Aug 28, 2025 • Pharmaceutical Executive
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight
Aug 28, 2025 • DelveInsight Business Research LLP
Amylyx Pharmaceuticals Says FDA Granted Voluntary Request To Withdraw Approval Of Relyvrio
Aug 28, 2025 • Reuters
Amylyx discontinues ORION program for AMX0035 in PSP
Aug 28, 2025 • Longevity.Technology - Latest News, Opinions, Analysis and Research
Amylyx Pharmaceuticals says FDA granted voluntary request to withdraw approval of Relyvrio
Aug 28, 2025 • MarketScreener
Victoria's Secret, Copper miners, Dell
Aug 28, 2025 • Reuters
Amylyx axes rare disease program after Relyvrio fails to beat placebo
Aug 27, 2025 • Fierce Biotech
Amylyx ends development of AMX0035 in rare neurodegenerative disease
Aug 27, 2025 • FirstWord Pharma
Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial
Aug 27, 2025 • Yahoo Finance
Amylyx to stop development of rare brain disorder drug after trial failure
Aug 27, 2025 • Reuters
Amylyx culls rare neurological disorder programme after trial failure
Aug 27, 2025 • Clinical Trials Arena
Amylyx Axes Drug Program for Rare Neurodegenerative Disorder
Aug 27, 2025 • BioSpace
After ALS trial fail, Amylyx pulls plug on another neuro trial
Aug 27, 2025 • The Business Journals
Mizuho raises Amylyx Pharmaceuticals stock price target to $12 on improved outlook
Aug 27, 2025 • Investing.com
Amylyx culls rare neurological disorder programme after trial failure
Aug 27, 2025 • Pharmaceutical Technology
Clinical Trial Setback: Amylyx's AMX0035 Shows No Benefit in Progressive Supranuclear Palsy Study
Aug 27, 2025 • Stock Titan
Amylyx to discontinue ORION program of AMX0035
Aug 27, 2025 • thefly.com
5 Major Wall Street Conferences in 9 Days: Amylyx Pharmaceuticals' Packed September Schedule
Aug 26, 2025 • Stock Titan
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
Aug 26, 2025 • Business Wire
Antisense Oligonucleotide Therapeutics Pipeline Market Landscape Report 2025 | Explore Clinical and Nonclinical Stages, Therapeutic Assessments, and the Future of ASO Therapies
Aug 8, 2025 • Research and Markets

Links

www.amylyx.comLinkedInX (Twitter)Crunchbase